Champions Cash vs Common Stock Total Equity Analysis

CSBR Stock

USD 4.31 0.02 0.46%

Champions Oncology financial indicator trend analysis is way more than just evaluating Champions Oncology prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Champions Oncology is a good investment. Please check the relationship between Champions Oncology Cash and its Common Stock Total Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Champions Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.

Cash vs Common Stock Total Equity

Cash vs Common Stock Total Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Champions Oncology Cash account and Common Stock Total Equity. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Champions Oncology's Cash and Common Stock Total Equity is 0.43. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Champions Oncology, assuming nothing else is changed. The correlation between historical values of Champions Oncology's Cash and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Champions Oncology are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Cash i.e., Champions Oncology's Cash and Common Stock Total Equity go up and down completely randomly.

Correlation Coefficient

0.43

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Cash

Cash refers to the most liquid asset of Champions Oncology, which is listed under current asset account on Champions Oncology balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Champions Oncology customers. The amounts must be unrestricted with restricted cash listed in a different Champions Oncology account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most indicators from Champions Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Champions Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Champions Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.At this time, Champions Oncology's Selling General Administrative is relatively stable compared to the past year. As of 11/29/2024, Sales General And Administrative To Revenue is likely to grow to 0.42, though Tax Provision is likely to grow to (30.4 K).

	2021	2022	2023	2024 (projected)
Gross Profit	25.5M	24.3M	20.8M	21.8M
Total Revenue	49.1M	53.9M	50.2M	52.7M

Gross Profit Total Revenue

Champions Oncology fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Other Liab	Other Assets
Total Assets		0.95	0.62	0.89	0.38	0.96	0.51	-0.67	0.73	0.49	0.96	-0.43	0.49	0.91	-0.2	0.74	0.77	-0.39	0.9	0.72	0.92	0.87	0.96	-0.2	-0.1	-0.58
Short Long Term Debt Total	0.95		0.6	0.86	0.27	0.99	0.71	-0.6	0.69	0.28	0.99	-0.51	0.28	0.91	-0.32	0.69	0.82	-0.21	0.89	0.63	0.92	0.92	0.83	-0.32	-0.21	-0.65
Other Current Liab	0.62	0.6		0.43	0.42	0.62	0.29	-0.5	0.29	0.34	0.62	-0.39	0.34	0.52	-0.33	0.59	0.5	-0.3	0.33	0.53	0.5	0.42	0.58	-0.33	-0.17	-0.25
Total Current Liabilities	0.89	0.86	0.43		0.0	0.89	0.66	-0.79	0.94	0.19	0.9	-0.16	0.19	0.96	-0.35	0.79	0.66	-0.36	0.86	0.78	0.96	0.94	0.81	-0.35	-0.11	-0.45
Total Stockholder Equity	0.38	0.27	0.42	0.0		0.25	-0.29	-0.1	-0.2	0.71	0.25	-0.42	0.71	0.09	0.27	0.17	0.0	-0.14	0.22	0.24	0.0	0.0	0.5	0.27	-0.01	-0.28
Property Plant And Equipment Net	0.96	0.99	0.62	0.89	0.25		0.72	-0.65	0.72	0.26	1.0	-0.49	0.26	0.94	-0.36	0.74	0.81	-0.23	0.89	0.68	0.94	0.92	0.84	-0.36	-0.2	-0.62
Net Debt	0.51	0.71	0.29	0.66	-0.29	0.72		-0.49	0.57	-0.47	0.71	-0.26	-0.47	0.75	-0.6	0.56	0.55	0.12	0.6	0.45	0.68	0.79	0.26	-0.6	-0.29	-0.4
Retained Earnings	-0.67	-0.6	-0.5	-0.79	-0.1	-0.65	-0.49		-0.75	-0.09	-0.67	-0.13	-0.09	-0.79	0.32	-0.96	-0.32	0.64	-0.59	-0.99	-0.69	-0.65	-0.62	0.32	0.14	-0.03
Accounts Payable	0.73	0.69	0.29	0.94	-0.2	0.72	0.57	-0.75		0.11	0.73	0.03	0.11	0.85	-0.28	0.71	0.54	-0.39	0.7	0.72	0.88	0.85	0.68	-0.28	-0.05	-0.35
Cash	0.49	0.28	0.34	0.19	0.71	0.26	-0.47	-0.09	0.11		0.27	-0.26	1.0	0.12	0.43	0.1	0.28	-0.42	0.3	0.19	0.24	0.08	0.7	0.43	0.13	-0.27
Non Current Assets Total	0.96	0.99	0.62	0.9	0.25	1.0	0.71	-0.67	0.73	0.27		-0.47	0.27	0.94	-0.35	0.75	0.81	-0.26	0.89	0.7	0.94	0.92	0.85	-0.35	-0.19	-0.6
Non Currrent Assets Other	-0.43	-0.51	-0.39	-0.16	-0.42	-0.49	-0.26	-0.13	0.03	-0.26	-0.47		-0.26	-0.24	0.2	-0.06	-0.47	-0.41	-0.34	0.08	-0.29	-0.25	-0.34	0.2	0.25	0.66
Cash And Short Term Investments	0.49	0.28	0.34	0.19	0.71	0.26	-0.47	-0.09	0.11	1.0	0.27	-0.26		0.12	0.43	0.1	0.28	-0.42	0.3	0.19	0.24	0.08	0.7	0.43	0.13	-0.27
Net Receivables	0.91	0.91	0.52	0.96	0.09	0.94	0.75	-0.79	0.85	0.12	0.94	-0.24	0.12		-0.38	0.84	0.69	-0.32	0.89	0.79	0.94	0.95	0.79	-0.38	-0.11	-0.47
Common Stock Total Equity	-0.2	-0.32	-0.33	-0.35	0.27	-0.36	-0.6	0.32	-0.28	0.43	-0.35	0.2	0.43	-0.38		-0.33	-0.2	-0.17	-0.22	-0.26	-0.32	-0.3	-0.01	1.0	0.33	0.18
Common Stock Shares Outstanding	0.74	0.69	0.59	0.79	0.17	0.74	0.56	-0.96	0.71	0.1	0.75	-0.06	0.1	0.84	-0.33		0.43	-0.55	0.64	0.96	0.73	0.69	0.66	-0.33	-0.17	-0.07
Non Current Liabilities Total	0.77	0.82	0.5	0.66	0.0	0.81	0.55	-0.32	0.54	0.28	0.81	-0.47	0.28	0.69	-0.2	0.43		-0.28	0.72	0.31	0.84	0.73	0.67	-0.2	-0.08	-0.53
Inventory	-0.39	-0.21	-0.3	-0.36	-0.14	-0.23	0.12	0.64	-0.39	-0.42	-0.26	-0.41	-0.42	-0.32	-0.17	-0.55	-0.28		-0.29	-0.63	-0.36	-0.21	-0.49	-0.17	-0.29	-0.27
Other Current Assets	0.9	0.89	0.33	0.86	0.22	0.89	0.6	-0.59	0.7	0.3	0.89	-0.34	0.3	0.89	-0.22	0.64	0.72	-0.29		0.62	0.88	0.87	0.83	-0.22	-0.07	-0.57
Other Stockholder Equity	0.72	0.63	0.53	0.78	0.24	0.68	0.45	-0.99	0.72	0.19	0.7	0.08	0.19	0.79	-0.26	0.96	0.31	-0.63	0.62		0.68	0.66	0.68	-0.26	-0.14	-0.03
Total Liab	0.92	0.92	0.5	0.96	0.0	0.94	0.68	-0.69	0.88	0.24	0.94	-0.29	0.24	0.94	-0.32	0.73	0.84	-0.36	0.88	0.68		0.94	0.83	-0.32	-0.11	-0.52
Property Plant And Equipment Gross	0.87	0.92	0.42	0.94	0.0	0.92	0.79	-0.65	0.85	0.08	0.92	-0.25	0.08	0.95	-0.3	0.69	0.73	-0.21	0.87	0.66	0.94		0.74	-0.3	-0.14	-0.61
Total Current Assets	0.96	0.83	0.58	0.81	0.5	0.84	0.26	-0.62	0.68	0.7	0.85	-0.34	0.7	0.79	-0.01	0.66	0.67	-0.49	0.83	0.68	0.83	0.74		-0.01	0.0	-0.52
Common Stock	-0.2	-0.32	-0.33	-0.35	0.27	-0.36	-0.6	0.32	-0.28	0.43	-0.35	0.2	0.43	-0.38	1.0	-0.33	-0.2	-0.17	-0.22	-0.26	-0.32	-0.3	-0.01		0.33	0.18
Other Liab	-0.1	-0.21	-0.17	-0.11	-0.01	-0.2	-0.29	0.14	-0.05	0.13	-0.19	0.25	0.13	-0.11	0.33	-0.17	-0.08	-0.29	-0.07	-0.14	-0.11	-0.14	0.0	0.33		0.07
Other Assets	-0.58	-0.65	-0.25	-0.45	-0.28	-0.62	-0.4	-0.03	-0.35	-0.27	-0.6	0.66	-0.27	-0.47	0.18	-0.07	-0.53	-0.27	-0.57	-0.03	-0.52	-0.61	-0.52	0.18	0.07

Click cells to compare fundamentals

Champions Oncology Account Relationship Matchups

Champions Oncology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	20.8M	27.6M	35.4M	34.3M	26.1M	27.4M
Short Long Term Debt Total	3.8M	9.6M	9.5M	8.6M	7.4M	7.8M
Other Current Liab	2.5M	2.2M	1.4M	1.2M	973K	739.7K
Total Current Liabilities	12.1M	11.2M	17.5M	21.7M	21.5M	22.6M
Total Stockholder Equity	5.3M	7.4M	9.1M	4.6M	(1.9M)	(1.8M)
Property Plant And Equipment Net	6.8M	14.6M	15.4M	14.5M	12.0M	12.6M
Net Debt	(4.5M)	4.9M	459K	(1.5M)	4.8M	5.1M
Retained Earnings	(72.7M)	(72.5M)	(72.0M)	(77.3M)	(84.6M)	(80.4M)
Accounts Payable	3.1M	1.9M	2.9M	5.3M	5.8M	6.1M
Cash	8.3M	4.7M	9.0M	10.1M	2.6M	3.7M
Non Current Assets Total	7.3M	15.0M	15.7M	14.9M	12.5M	13.1M
Cash And Short Term Investments	8.3M	4.7M	9.0M	10.1M	2.6M	3.7M
Net Receivables	4.8M	7.0M	9.5M	8.0M	9.5M	10.0M
Common Stock Shares Outstanding	11.8M	14.6M	14.2M	13.5M	13.5M	14.2M
Liabilities And Stockholders Equity	20.8M	27.6M	35.4M	34.3M	26.1M	27.4M
Non Current Liabilities Total	3.3M	9.0M	8.8M	7.9M	6.5M	6.8M
Other Current Assets	385K	957K	2.3M	1.3M	1.5M	1.6M
Other Stockholder Equity	78.0M	79.9M	81.1M	81.9M	82.7M	86.8M
Total Liab	15.4M	20.2M	26.3M	29.7M	28.0M	29.4M
Property Plant And Equipment Gross	6.8M	14.6M	15.4M	14.5M	22.4M	23.5M
Total Current Assets	13.5M	12.6M	19.7M	19.5M	13.6M	14.3M
Other Liab	178K	181K	391K	551K	633.7K	500.9K
Short Term Debt	628K	818K	2.1M	2.4M	2.7M	2.8M
Property Plant Equipment	6.8M	14.6M	15.4M	14.5M	16.7M	17.5M
Current Deferred Revenue	5.8M	6.3M	11.1M	12.8M	12.1M	12.7M
Retained Earnings Total Equity	(72.7M)	(72.5M)	(72.0M)	(77.3M)	(69.6M)	(73.1M)
Net Tangible Assets	5.0M	7.1M	8.8M	4.3M	4.9M	3.9M
Capital Surpluse	78.0M	79.9M	81.1M	82.0M	94.3M	77.6M

Pair Trading with Champions Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving against Champions Stock

0.49	VERV	Verve Therapeutics	Pair Corr
0.46	DRUG	Bright Minds Biosciences	Pair Corr
0.36	EQ	Equillium	Pair Corr
0.35	VANI	Vivani Medical	Pair Corr

The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.

The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Champions Stock Analysis

When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC